Abstract
CD25+ FOXP3+CD4+ T cells (Treg) have been considered to play an important role in immune tolerance against several tumor antigens. It has also been indicated that high-level expression of FOXP3 (FOXP3high) is sufficient to confer suppressive activity to normal non-Treg. Here, we showed for the first time that vascular endothelial growth factor receptor 2 (VEGFR2) is selectively expressed by FOXP3high but not FOXP3low Treg. Such VEGFR2+ Treg exist in several tissues including PBMC and malignant effusion-derived lymphocytes. In conclusion, VEGFR2 may be a novel target for controlling Treg with highly suppressive function.
Original language | English |
---|---|
Pages (from-to) | 197-203 |
Number of pages | 7 |
Journal | European Journal of Immunology |
Volume | 40 |
Issue number | 1 |
DOIs | |
Publication status | Published - Jan 2010 |
All Science Journal Classification (ASJC) codes
- Immunology and Allergy
- Immunology